



HEALTHCARE COMMITTEE

The Healthcare Committee includes members from three major industry subsegments:

1) Pharmaceuticals, 2) Medical Devices, and 3) Hospitals, Clinics, and Healthcare Services.

The Healthcare Committee's 2023 strategic plan is grouped around three types of activities: *Advocacy, Business, and Community (ABCs)*.

Committee Priorities:

Advocacy-High

Business-Low

Community-Low

Mission

To strengthen the long-term, constructive cooperation in the healthcare field between U.S. and China, to support capacity and capability building in the healthcare system in China, and to promote a healthy environment for the growth of the healthcare industry in China while helping American companies thrive in China market.

Main Activities

Healthcare Chapter in annual AmCham China *White Paper* (2023 Healthcare *White Paper*, special edition).

Research program with stakeholders at the central level, e.g., FDA (US Food and Drug Administration), DRC (Development Research Center), NHC (National Health Commission), NMPA (National Medical Products Administration), etc.

Call-for-Comments to help members deliver their messages, suggestions, and feedback to the central government regarding new policies and regulations

Youth Physician Training Program

Regular workshops and one-day forums focusing on trending topics

Regular networking events (mixers, breakfast meetings, etc.)

Delegation visits to Hubei, Jiangxi, Fujian, Tianjin, Jilin, Henan, Sichuan and more.

Leadership



Co-Chair:
Jeffrey Bernstein,
UPMC



Co-Chair:
Alice Xu,
Boston Scientific



Co-Chair:
Roberta Lipson,
United Family
Healthcare



Co-Chair:
Jeffrey Que,
Johnson & Johnson



Co-Chair:
Rong Zheng,
Merck Healthcare

Member Profile

Member Companies

80+

Committee Subscribes

>200

2023 Committee Strategic Focus

Advocacy (A)

High Priority

China's P.R.C Regulation on the Management of Human Genetic Resources

China's volume-based procurement scheme (VBP)

Payment based on Diagnosis Related Groups (DRG)

Health Data Protection

Health Supply Chain Localization

Administrative Measures for the Import of Drugs

Approval of clinical trial applications for biologics produced in stages

Medicines Patent Pool

How Drugs Review Process Reform encourages Drug innovation in China

FDA Regulation of Over-the-Counter (OTC) Drugs Review Process' inspiration to China

China's Negative List for Pharmaceuticals

National essential drug list adjustment

2023 Working Plan (Subject to Change)

	Q1	Q2	Q3	Q4
White Paper	• Drafting & Translations	• Publication	• Delivery	• Delivery
Delegation Visit	• Hubei	• Jiangxi, Tianjin, Macau, Sichuan, Henan	• Jilin	• Guangdong
Forums/Workshops	• /	• 15 April	• TBD	• TBD
Mixer	• 16 Feb	• TBD	• TBD	• TBD
Breakfast Meeting	• 28 Feb	• TBD	• TBD	• TBD

Active Committee Members

3M	Cordis	United Family Healthcare
Abbvie Pharmaceutical	Edwards Medical Products	Novartis Group
Abbott	GE Healthcare	Organon
Accuray	Gilead Sciences	Pfizer
Alcon	GSK	Philips
Amgen	IBM	Parexel International
APCO Worldwide	Illumina Scientific	Roche Diagnostics
AstraZeneca	Eli Lilly and Company	Sanofi
Bayer	Johnson & Johnson	Stryker
Becton Dickinson Medical Devices	Kavo Group	Thermo Fisher Scientific
Bio-Rad Laboratories	Medtronic	Varian Medical Systems
Boston Scientific	Merck	Viatrix Pharmaceuticals Co., Ltd.
Coloplast Medical Devices	MSD	Zimmer